-
1
-
-
79952420498
-
Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa
-
[1] Kanj, S.S., Kanafani, Z.A., Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86 (2011), 250–259.
-
(2011)
Mayo Clin Proc
, vol.86
, pp. 250-259
-
-
Kanj, S.S.1
Kanafani, Z.A.2
-
2
-
-
84879017742
-
Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)
-
[2] Sheng, W.H., Badal, R.E., Hsueh, P.R., Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 57 (2013), 2981–2988.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, pp. 2981-2988
-
-
Sheng, W.H.1
Badal, R.E.2
Hsueh, P.R.3
-
3
-
-
79952111025
-
Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections
-
[3] Bush, K., Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections. Crit Care, 14, 2010, 224.
-
(2010)
Crit Care
, vol.14
, pp. 224
-
-
Bush, K.1
-
4
-
-
84871994820
-
2013 WSES guidelines for management of intra-abdominal infections
-
[4] Sartelli, M., Viale, P., Catena, F., Ansaloni, L., Moore, E., Malangoni, M., et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg, 8, 2013, 3.
-
(2013)
World J Emerg Surg
, vol.8
, pp. 3
-
-
Sartelli, M.1
Viale, P.2
Catena, F.3
Ansaloni, L.4
Moore, E.5
Malangoni, M.6
-
5
-
-
73649114948
-
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
-
[5] Solomkin, J., Mazuski, J.E., Bradley, J.S., Rodvold, K.A., Goldstein, E.J., Baron, E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50 (2010), 133–164.
-
(2010)
Clin Infect Dis
, vol.50
, pp. 133-164
-
-
Solomkin, J.1
Mazuski, J.E.2
Bradley, J.S.3
Rodvold, K.A.4
Goldstein, E.J.5
Baron, E.J.6
-
6
-
-
84878337468
-
Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections
-
[6] Solomkin, J., Ristagno, R.L., Das, A.F., Cone, J.B., Wilson, S.E., Rotstein, O.D., et al. Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis 56 (2013), 1765–1773.
-
(2013)
Clin Infect Dis
, vol.56
, pp. 1765-1773
-
-
Solomkin, J.1
Ristagno, R.L.2
Das, A.F.3
Cone, J.B.4
Wilson, S.E.5
Rotstein, O.D.6
-
7
-
-
84887157965
-
A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011
-
[7] Morrissey, I., Hackel, M., Badal, R., Bouchillon, S., Hawser, S., Biedenbach, D., A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 6 (2013), 1335–1346.
-
(2013)
Pharmaceuticals (Basel)
, vol.6
, pp. 1335-1346
-
-
Morrissey, I.1
Hackel, M.2
Badal, R.3
Bouchillon, S.4
Hawser, S.5
Biedenbach, D.6
-
8
-
-
85014571133
-
Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)
-
[8] Jean, S.S., Hsueh, P.R., SMART Asia-Pacific Group. Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 72 (2017), 166–171.
-
(2017)
J Antimicrob Chemother
, vol.72
, pp. 166-171
-
-
Jean, S.S.1
Hsueh, P.R.2
-
9
-
-
84867166640
-
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions
-
[9] Tzouvelekis, L.S., Markogiannakis, A., Psichogiou, M., Tassios, P.T., Daikos, G.L., Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25 (2012), 682–707.
-
(2012)
Clin Microbiol Rev
, vol.25
, pp. 682-707
-
-
Tzouvelekis, L.S.1
Markogiannakis, A.2
Psichogiou, M.3
Tassios, P.T.4
Daikos, G.L.5
-
10
-
-
84884764949
-
Kinetics of avibactam inhibition against class A, C, and D β-lactamases
-
[10] Ehmann, D.E., Jahic, H., Ross, P.L., Gu, R.F., Hu, J., Durand-Reville, T.F., et al. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 288 (2013), 27960–27971.
-
(2013)
J Biol Chem
, vol.288
, pp. 27960-27971
-
-
Ehmann, D.E.1
Jahic, H.2
Ross, P.L.3
Gu, R.F.4
Hu, J.5
Durand-Reville, T.F.6
-
11
-
-
79955537450
-
Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases
-
[11] Lagace-Wiens, P.R., Tailor, F., Simner, P., DeCorby, M., Karlowsky, J.A., Walkty, A., et al. Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrob Agents Chemother 55 (2011), 2434–2437.
-
(2011)
Antimicrob Agents Chemother
, vol.55
, pp. 2434-2437
-
-
Lagace-Wiens, P.R.1
Tailor, F.2
Simner, P.3
DeCorby, M.4
Karlowsky, J.A.5
Walkty, A.6
-
12
-
-
82955187694
-
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
-
[12] Aktas, Z., Kayacan, C., Oncul, O., In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 39 (2012), 86–89.
-
(2012)
Int J Antimicrob Agents
, vol.39
, pp. 86-89
-
-
Aktas, Z.1
Kayacan, C.2
Oncul, O.3
-
13
-
-
84928893993
-
In vitro antibacterial activity of the ceftazidime–avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases
-
[13] Levasseur, P., Girard, A.M., Miossec, C., Pace, J., Coleman, K., In vitro antibacterial activity of the ceftazidime–avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother 59 (2015), 1931–1934.
-
(2015)
Antimicrob Agents Chemother
, vol.59
, pp. 1931-1934
-
-
Levasseur, P.1
Girard, A.M.2
Miossec, C.3
Pace, J.4
Coleman, K.5
-
14
-
-
84908271938
-
In vivo efficacy of humanized exposures of ceftazidime–avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates
-
[14] MacVane, S.H., Crandon, J.L., Nichols, W.W., Nicolau, D.P., In vivo efficacy of humanized exposures of ceftazidime–avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother 58 (2014), 6913–6919.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 6913-6919
-
-
MacVane, S.H.1
Crandon, J.L.2
Nichols, W.W.3
Nicolau, D.P.4
-
15
-
-
85082221247
-
Prescribing information: AVYCAZ (ceftazidime–avibactam) for injection, for intravenous use
-
Available from: [Accessed 20 August 2016]
-
[15] Actavis Inc., Prescribing information: AVYCAZ (ceftazidime–avibactam) for injection, for intravenous use. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494lbl.pdf, 2015 [Accessed 20 August 2016].
-
(2015)
-
-
Actavis Inc.1
-
16
-
-
84870399321
-
Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
-
[16] Vazquez, J.A., Gonzalez Patzan, L.D., Stricklin, D., Duttaroy, D.D., Kreidly, Z., Lipka, J., et al. Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28 (2012), 1921–1931.
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 1921-1931
-
-
Vazquez, J.A.1
Gonzalez Patzan, L.D.2
Stricklin, D.3
Duttaroy, D.D.4
Kreidly, Z.5
Lipka, J.6
-
17
-
-
84877123198
-
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial
-
[17] Lucasti, C., Popescu, I., Ramesh, M.K., Lipka, J., Sable, C., Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68 (2013), 1183–1192.
-
(2013)
J Antimicrob Chemother
, vol.68
, pp. 1183-1192
-
-
Lucasti, C.1
Popescu, I.2
Ramesh, M.K.3
Lipka, J.4
Sable, C.5
-
18
-
-
84971578709
-
Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection—results from a randomised, controlled, double-blind, phase 3 program
-
[18] Mazuski, J.E., Gasink, L.B., Armstrong, J., Broadhurst, H., Stone, G.G., Rank, D., et al. Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection—results from a randomised, controlled, double-blind, phase 3 program. Clin Infect Dis 62 (2016), 1380–1389.
-
(2016)
Clin Infect Dis
, vol.62
, pp. 1380-1389
-
-
Mazuski, J.E.1
Gasink, L.B.2
Armstrong, J.3
Broadhurst, H.4
Stone, G.G.5
Rank, D.6
-
19
-
-
84995390345
-
Ceftazidime–avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program
-
[19] Wagenlehner, F.M., Sobel, J.D., Newell, P., Armstrong, J., Huang, X., Stone, G.G., et al. Ceftazidime–avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63 (2016), 754–762.
-
(2016)
Clin Infect Dis
, vol.63
, pp. 754-762
-
-
Wagenlehner, F.M.1
Sobel, J.D.2
Newell, P.3
Armstrong, J.4
Huang, X.5
Stone, G.G.6
-
20
-
-
84963954564
-
Results from REPRISE, a randomised, pathogen-directed phase 3 study of ceftazidime–avibactam or best available therapy in patients with ceftazidime-resistant complicated urinary tract infections or complicated intra-abdominal infections
-
[20] Carmeli, Y., Armstrong, J., Laud, P.J., Newell, P., Stone, G., Wardman, A., et al. Results from REPRISE, a randomised, pathogen-directed phase 3 study of ceftazidime–avibactam or best available therapy in patients with ceftazidime-resistant complicated urinary tract infections or complicated intra-abdominal infections. Lancet Infect Dis 16 (2016), 661–673.
-
(2016)
Lancet Infect Dis
, vol.16
, pp. 661-673
-
-
Carmeli, Y.1
Armstrong, J.2
Laud, P.J.3
Newell, P.4
Stone, G.5
Wardman, A.6
-
21
-
-
84976585919
-
Summary of product characteristics: Zavicefta
-
Available from: [Accessed 20 August 2016]
-
[21] AstraZeneca Ltd, Summary of product characteristics: Zavicefta. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf, 2016 [Accessed 20 August 2016].
-
(2016)
-
-
AstraZeneca Ltd1
-
22
-
-
84926365447
-
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
-
[22] Baietto, L., Corcione, S., Pacini, G., Perri, G.D., D'Avolio, A., De Rosa, F.G., A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?. Curr Drug Metab 15 (2014), 581–598.
-
(2014)
Curr Drug Metab
, vol.15
, pp. 581-598
-
-
Baietto, L.1
Corcione, S.2
Pacini, G.3
Perri, G.D.4
D'Avolio, A.5
De Rosa, F.G.6
-
23
-
-
49949090275
-
The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies
-
[23] Yasuda, S.U., Zhang, L., Huang, S.M., The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84 (2008), 417–423.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 417-423
-
-
Yasuda, S.U.1
Zhang, L.2
Huang, S.M.3
-
24
-
-
33646696219
-
Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement
-
CLSI Wayne, PA Document M100-S22
-
[24] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. 2012, CLSI, Wayne, PA Document M100-S22.
-
(2012)
-
-
Clinical and Laboratory Standards Institute1
-
25
-
-
0021832508
-
Comparative analysis of two rates
-
[25] Miettinen, O., Nurminen, M., Comparative analysis of two rates. Stat Med 4 (1985), 213–226.
-
(1985)
Stat Med
, vol.4
, pp. 213-226
-
-
Miettinen, O.1
Nurminen, M.2
-
26
-
-
44849104852
-
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study
-
[26] Lucasti, C., Jasovich, A., Umeh, O., Jiang, J., Kaniga, K., Friedland, I., Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 30 (2008), 868–883.
-
(2008)
Clin Ther
, vol.30
, pp. 868-883
-
-
Lucasti, C.1
Jasovich, A.2
Umeh, O.3
Jiang, J.4
Kaniga, K.5
Friedland, I.6
-
27
-
-
84859625873
-
Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial
-
[27] Qvist, N., Warren, B., Leister-Tebbe, H., Zito, E.T., Pedersen, R., McGovern, P.C., et al. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect (Larchmt) 13 (2012), 102–109.
-
(2012)
Surg Infect (Larchmt)
, vol.13
, pp. 102-109
-
-
Qvist, N.1
Warren, B.2
Leister-Tebbe, H.3
Zito, E.T.4
Pedersen, R.5
McGovern, P.C.6
-
28
-
-
84929206762
-
Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)
-
[28] Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60 (2015), 1462–1471.
-
(2015)
Clin Infect Dis
, vol.60
, pp. 1462-1471
-
-
Solomkin, J.1
Hershberger, E.2
Miller, B.3
Popejoy, M.4
Friedland, I.5
Steenbergen, J.6
-
29
-
-
69949120498
-
Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections
-
[29] Solomkin, J., Zhao, Y.P., Ma, E.L., Chen, M.J., Hampel, B., Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 34 (2009), 439–445.
-
(2009)
Int J Antimicrob Agents
, vol.34
, pp. 439-445
-
-
Solomkin, J.1
Zhao, Y.P.2
Ma, E.L.3
Chen, M.J.4
Hampel, B.5
-
30
-
-
84957426156
-
A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime–avibactam in healthy Chinese subjects
-
[30] Li, J., Learoyd, M., Qiu, F., Zhu, L., Edeki, T., A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime–avibactam in healthy Chinese subjects. Clin Drug Investig 36 (2016), 119–126.
-
(2016)
Clin Drug Investig
, vol.36
, pp. 119-126
-
-
Li, J.1
Learoyd, M.2
Qiu, F.3
Zhu, L.4
Edeki, T.5
-
31
-
-
84937627900
-
Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers
-
[31] Tominaga, N., Edeki, T., Li, J., Learoyd, M., Bouw, M.R., Das, S., Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers. J Infect Chemother 21 (2015), 551–558.
-
(2015)
J Infect Chemother
, vol.21
, pp. 551-558
-
-
Tominaga, N.1
Edeki, T.2
Li, J.3
Learoyd, M.4
Bouw, M.R.5
Das, S.6
-
32
-
-
84906085321
-
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane–tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections
-
[32] Lucasti, C., Hershberger, E., Miller, B., Yankelev, S., Steenbergen, J., Friedland, I., et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane–tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 58 (2014), 5350–5357.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 5350-5357
-
-
Lucasti, C.1
Hershberger, E.2
Miller, B.3
Yankelev, S.4
Steenbergen, J.5
Friedland, I.6
-
33
-
-
85082208485
-
© 1g injection SPC
-
Available from: [Accessed 20 August 2016]
-
© 1g injection SPC. Available from: http://www.medicines.org.uk/emc/document.aspx?documentid=19176&docType=SPC, 2016 [Accessed 20 August 2016].
-
(2016)
-
-
GlaxoSmithKline1
|